Tacrolimus as an Effective and Durable Second-Line Treatment for Chronic Autoimmune Hepatitis: A Multicentric Study

Area of Science:

• Hepatology
• Immunology
• Pharmacology

Background:

• Autoimmune hepatitis (AIH) is a chronic liver disease with potential progression to severe outcomes like liver failure and cancer.
• Many AIH patients experience treatment failure or severe side effects with standard first-line therapies.

Purpose of the Study:

• To evaluate the safety and effectiveness of tacrolimus as a second-line treatment option for patients diagnosed with autoimmune hepatitis.

Main Methods:

• A multicenter retrospective study analyzed AIH patients receiving tacrolimus for at least three months as a subsequent therapy.
• Effectiveness was determined by the complete normalization of liver enzymes (transaminases) and immunoglobulin G (IgG) levels.

Main Results:

• Tacrolimus proved effective in 78% of the 23 analyzed AIH patients, leading to sustained improvements in liver enzymes and IgG.
• The drug was initiated due to non-efficacy (87%) or toxicity (13%) of prior treatments.
• Only one patient discontinued tacrolimus due to adverse events (neuropathy, ototoxicity); responders were significantly older at AIH diagnosis.

Conclusions:

• Tacrolimus is a well-tolerated and effective second-line therapeutic option for autoimmune hepatitis.
• It offers a viable alternative for AIH patients who have not responded to or cannot tolerate first-line treatments.